What is he best known for?
The fields of study he is best known for:
Viktor Magdolen mostly deals with Urokinase receptor, Molecular biology, Plasminogen activator, Biochemistry and Cancer research.
His Urokinase receptor study results in a more complete grasp of Receptor.
His Molecular biology study incorporates themes from Amino acid, Saccharomyces cerevisiae, Cell growth, Monoclonal antibody and Peptide.
His work carried out in the field of Plasminogen activator brings together such families of science as Integrin and Immunology.
His biological study spans a wide range of topics, including Cancer and Metastasis.
His research integrates issues of Cancer cell, Urokinase and Pathology in his study of Metastasis.
His most cited work include:
- Clinical impact of the plasminogen activation system in tumor invasion and metastasis : Prognostic relevance and target for therapy (362 citations)
- Specificity profiling of seven human tissue kallikreins reveals individual subsite preferences. (137 citations)
- Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer (135 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Cancer research, Urokinase receptor, Molecular biology, Plasminogen activator and Urokinase.
His Cancer research study combines topics from a wide range of disciplines, such as Cancer, Ovarian cancer, Metastasis, Immunology and Pathology.
His research in Urokinase receptor intersects with topics in Serine protease, Cancer cell, Plasminogen activator inhibitor-1 and Tumor progression.
Cell is closely connected to Cell growth in his research, which is encompassed under the umbrella topic of Molecular biology.
Within one scientific family, Viktor Magdolen focuses on topics pertaining to Plasmin under Plasminogen activator, and may sometimes address concerns connected to Proteases.
His biological study spans a wide range of topics, including Urokinase Plasminogen Activator, Aryl and Peptide.
He most often published in these fields:
- Cancer research (36.40%)
- Urokinase receptor (30.54%)
- Molecular biology (25.94%)
What were the highlights of his more recent work (between 2017-2021)?
- Cancer research (36.40%)
- Internal medicine (12.13%)
- Oncology (10.46%)
In recent papers he was focusing on the following fields of study:
Viktor Magdolen mainly investigates Cancer research, Internal medicine, Oncology, Kallikrein and Ovarian cancer.
His research integrates issues of Immunohistochemistry, Tumor microenvironment, KLK7, Breast cancer and In vivo in his study of Cancer research.
His study looks at the intersection of Tumor microenvironment and topics like Metastasis with Cancer biomarkers.
Viktor Magdolen combines subjects such as Biomarker, Triple-negative breast cancer and Disease with his study of Oncology.
Kallikrein is a subfield of Biochemistry that Viktor Magdolen explores.
In his study, which falls under the umbrella issue of Ovarian cancer, Real-time polymerase chain reaction and Stage is strongly linked to Clinical significance.
Between 2017 and 2021, his most popular works were:
- Brain-related proteins as potential CSF biomarkers of Alzheimer's disease: A targeted mass spectrometry approach. (20 citations)
- Surface loops of trypsin-like serine proteases as determinants of function. (15 citations)
- Kallikrein-related peptidases 4, 5, 6 and 7 regulate tumour-associated factors in serous ovarian cancer (14 citations)
In his most recent research, the most cited papers focused on:
Viktor Magdolen spends much of his time researching Cancer research, Ovarian cancer, KLK7, Kallikrein and Internal medicine.
Viktor Magdolen has researched Cancer research in several fields, including Immunohistochemistry, CX3CR1 and Tumor microenvironment.
His KLK7 research focuses on KLK5 and how it relates to Cancer biomarkers, microRNA and Metastasis.
His Kallikrein study introduces a deeper knowledge of Biochemistry.
His study in Internal medicine is interdisciplinary in nature, drawing from both KLK4 and Oncology.
His Oncology research is multidisciplinary, relying on both Breast cancer, Triple-negative breast cancer and Amyloid beta, Disease.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
